These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1167 related items for PubMed ID: 19396723

  • 1. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
    Yokoyama T, Uematsu K, Watanabe T, Sasaki K, Kumon H, Nagai A, Okayama Urological Research Group.
    Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
    [Abstract] [Full Text] [Related]

  • 2. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z.
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [Abstract] [Full Text] [Related]

  • 3. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
    Maruyama O, Kawachi Y, Hanazawa K, Koizumi K, Yamashita R, Sugimura S, Honda S, Sugiyama Y, Saitoh T, Noto K.
    Int J Urol; 2006 Oct; 13(10):1280-5. PubMed ID: 17010005
    [Abstract] [Full Text] [Related]

  • 4. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA, Roehrborn CG, Gong J, Sun F, Guan Z.
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, Ishizuka O, Ozono S, Gotoh M, Sugiyama T, Seki N, Yoshida M, Japanese Solifenacin Study Group.
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [Abstract] [Full Text] [Related]

  • 9. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z.
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [Abstract] [Full Text] [Related]

  • 10. [Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms].
    Ge JP, Gong J, Ma HQ, Wei W, Shang XJ, Zhang ZY, Xu S, Wang D, Gao JP.
    Zhonghua Nan Ke Xue; 2008 Oct; 14(10):927-30. PubMed ID: 19157107
    [Abstract] [Full Text] [Related]

  • 11. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
    Yokoyama T, Kumon H, Nasu Y, Takamoto H, Watanabe T.
    Int J Urol; 2006 Jul; 13(7):932-8. PubMed ID: 16882058
    [Abstract] [Full Text] [Related]

  • 12. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Roehrborn CG, Kaplan SA, Jones JS, Wang JT, Bavendam T, Guan Z.
    Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y, Zhao XF, Li HZ, Wang W, Zhang Y, Xiao H, Zhang X.
    Chin Med J (Engl); 2007 Mar 05; 120(5):370-4. PubMed ID: 17376305
    [Abstract] [Full Text] [Related]

  • 14. Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study.
    Ukimura O, Kanazawa M, Fujihara A, Kamoi K, Okihara K, Miki T, Kyoto Prefectural University of Medicine Benign Prostatic Hypertrophy Research Group.
    Int J Urol; 2008 Dec 05; 15(12):1049-54. PubMed ID: 19120513
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
    Awa Y, Suzuki H, Hamano S, Okano T, Sakurayama Y, Ohki T, Egoshi K, Ota S, Mori I, Ichikawa T.
    Int J Urol; 2008 Aug 05; 15(8):709-15. PubMed ID: 18662175
    [Abstract] [Full Text] [Related]

  • 17. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia.
    Takahashi S, Tajima A, Matsushima H, Kawamura T, Tominaga T, Kitamura T.
    Int J Urol; 2006 Jan 05; 13(1):15-20. PubMed ID: 16448426
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication].
    Sakai H, Igawa T, Onita T, Furukawa M, Hakariya T, Hayashi M, Matsuya F, Shida Y, Nishimura N, Yogi Y, Tsurusaki T, Takehara K, Nomata K, Shiraishi K, Shono T, Aoki D, Kanetake H.
    Hinyokika Kiyo; 2011 Jan 05; 57(1):7-13. PubMed ID: 21304253
    [Abstract] [Full Text] [Related]

  • 20. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
    Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W.
    J Urol; 2009 Dec 05; 182(6):2825-30. PubMed ID: 19837435
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.